Stake logo

ASRT

Assertio Holdings, Inc.

About ASRT

Assertio Holdings, Inc. is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. The Company's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The Company has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

Buy US stocks in Australia starting with ASRT. Open an account and start investing today!

Market Capitalisation

$207.18M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

967.66K

High today

$4.34

Low today

$4.08

Open price

$4.33

52-week high

$4.44

52-week low

$1.86


ASRT FAQs

One share of Assertio Holdings, Inc. is valued at $4.13.

The ticker symbol for Assertio Holdings, Inc. is ASRT.

To buy ASRT stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in ASRT

As of 27/01/2023 Assertio Holdings, Inc. has a market cap of $207M.

The Assertio Holdings, Inc. 52-week high stock price is $4.44.

The Assertio Holdings, Inc. 52-week low stock price is $1.86.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.